We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Guide to Recent Biosimilar Activity by FDA and in the Supreme Court

16 March 2017

Biosimilars Law Blog

The U.S. Food and Drug Administration (FDA) recently completed a flurry of activity to help define the biosimilar pathway, including issuing final guidances on biosimilar clinical pharmacology and biologics non-proprietary naming, as well as a draft guidance on biosimilar interchangeability. In parallel, litigation that should clarify the BPCIA patent resolution process, including timing of the biosimilar applicant's notice of commercial marketing is proceeding through the Supreme Court.

Read More: Guide to Recent Biosimilar Activity by FDA and in the Supreme Court

Contacts

Loading data